Verition Fund Management
EW icon

Verition Fund Management’s Edwards Lifesciences EW Stock Holding History

Verition Fund Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,700
Closed -$997K – 2684
2025
Q4 		$997K Sell
11,700
-82,200
-88% -$6.75M ﹤0.01% 2161
2025
Q3 		$7.3M Buy
93,900
+2,400
+3% +$188K 0.03% 770
2025
Q2 		$7.16M Buy
91,500
+31,800
+53% +$2.37M 0.03% 760
2025
Q1 		$4.33M Buy
+59,700
New +$4.27M 0.02% 950
2024
Q3 		– Sell
-19,700
Closed -$1.82M – 3280
2024
Q2 		$1.82M Buy
19,700
+15,300
+348% +$1.35M 0.01% 1326
2024
Q1 		$420K Buy
+4,400
New +$370K ﹤0.01% 2102
2023
Q1 		– Sell
-3,300
Closed -$246K – 2260
2022
Q4 		$246K Sell
3,300
-11,600
-78% -$894K ﹤0.01% 1614
2022
Q3 		$1.23M Buy
+14,900
New +$1.43M 0.01% 1252
2022
Q2 		– Sell
-16,000
Closed -$1.88M – 2563
2022
Q1 		$1.88M Buy
16,000
+1,100
+7% +$123K 0.02% 1015
2021
Q4 		$1.93M Buy
+14,900
New +$1.74M 0.01% 911

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Verition Fund Management's EW Position: Q2 2026 in Review

Verition Fund Management increased its Edwards Lifesciences (EW) stake by 3,223% in Q2 2026, buying an estimated $16.3M and bringing the position to 200,695 shares worth $18.2M. The position accounts for 0.09% of the portfolio, ranked #226.

Verition Fund Management first reported a position in EW in Q3 2013 and has held it in 34 quarters since. 1,338 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Verition Fund Management held 200,695 shares of Edwards Lifesciences worth $18.2M as of Q2 2026.
  • Verition Fund Management bought 194,655 Edwards Lifesciences shares in Q2 2026, an estimated $16.3M.
  • Edwards Lifesciences made up 0.09% of Verition Fund Management's portfolio in Q2 2026, its #226 holding.
  • Verition Fund Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 34 quarters since.
  • 1,338 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.